Marker Therapeutics (FRA:GX1) Institutional Ownership : 4.24% (As of Jan. 18, 2025)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Marker Therapeutics's institutional ownership is 4.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Marker Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Marker Therapeutics's Float Percentage Of Total Shares Outstanding is 76.87%.

Marker Therapeutics Institutional Ownership Historical Data

The historical data trend for Marker Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Institutional Ownership Chart

Marker Therapeutics Historical Data

The historical data trend for Marker Therapeutics can be seen below:

	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31
Institutional Ownership	4.71	4.70	4.75	4.88	4.97	5.08	5.12	5.15	5.11	4.24

Marker Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Marker Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

9350 Kirby Drive, Suite 300, Houston, TX, USA, 77054

Website

http//www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics Headlines

No Headlines